The purpose of this resource is to provide tissue, cells and pathology services to all 4 research projects and to career or research development awardees covered by this application. To achieve these goals, we have integrated pathology resources from the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM) and its affiliated institutions, with those from The Methodist Hospital. This integration both ensures adequate sample numbers and the timely delivery of tissue/cell samples for the needs of project investigators. The core acquires tissues for banking from lymphoma and CLL patients at affiliated hospitals in the Texas Medical Center, exploiting tissue collection and distribution systems that are already in place and that meet TCGA guidelines. Over the past 4 years, the core has successfully provided fresh cells and tissue, FFPE tissue, DNA, and RNA, tissue microarrays, marrow and serum to SPORE and external investigators. The core also provides pathology services, including routine tissue preparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays, flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. In addition, the core contains a cancer genetics laboratory for specialized molecular studies, including FISH and sequencing. These resources are provided by expert pathologists, histotechnologists and molecular biologists with substantial experience in providing core services to SPORE investigators. Finally, the bioinformatics group has expertise in working with the BCM Breast SPOREs to utilize CaTissue resources and has developed both bioinformatics and tissue-banking software needs for the lymphoma SPORE.

Public Health Relevance

The Biospecimen and Pathology Core coljects biospecimens needed by all investigators in this SPORE as well as for other investigators performing lymphoma research for their translational research projects. It provides pathology services to investigators and supports the clinical trials

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-08
Application #
8724184
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
$280,412
Indirect Cost
$67,179
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 270 publications